Introduction To benefit symptomatic patients with moderate-to-severe COPD not managed by single bronchodilator, COPD management strategies recommend combining bronchodilators with different mechanisms. We compared, once-daily dual bronchodilation by co-administration of the long-acting muscarinic antagonist (LAMA) glycopyrronium 50 g (GLY) and the long-acting β_2 -agonist (LABA) indacaterol 150 g (IND), with IND 150 g monotherapy.

Methods In this randomised, multicentre, placebo-controlled, double-blind, parallel-group study, patients with moderate-to-severe COPD were administered with GLY + IND or IND + placebo (1:1; all delivered via Breezhaler[®] device) for 12 weeks. We assessed lung function, dyspnoea (via the transition dyspnoea index [TDI]), patient-reported symptoms, and safety and tolerability over 12 weeks.

Results Of the 449 patients randomised (GLY + IND [n = 226]; IND [n = 223]), 94.0% completed the study. At Week12, GLY + IND demonstrated a statistically significant improvement in mean trough forced expiratory volume in one second (FEV₁) over IND (least squares mean treatment difference [Td]: 64 mL; p < 0.001). Significantly greater improvements in FEV₁ area under curve from 30 min to 4h (FEV₁AUC_{30min-4h}) and trough forced vital capacity were observed with GLY + IND vs IND on Day1 (Td: 105 mL, 112 mL, respectively) and at Week12 (Td: 111 mL, 93 mL, respectively), all p < 0.01. GLY + IND demonstrated significant improvements in inspiratory capacity versus IND at most timepoints on Day1 and Week12 (Td: 59 to 159 mL). GLY + IND significantly improved TDI total score versus IND (Td: 0.49, p = 0.037) and a higher proportion of patients on GLY + IND achieved a clinically meaningful improvement (≥ 1 point) versus IND at Week12 (odds ratio 1.97 favouring GLY + IND; p = 0.004). GLY + IND was also associated with significantly greater improvements in mean day-time respiratory symptom score and the percentage of days being able to perform usual daily activities vs IND over 12 weeks of treatment (Td: -0.1 and 6.2, respectively; both p < 0.05). The overall incidence of adverse events (AEs) and serious AEs (SAEs) was comparable for the GLY + IND and IND groups (AEs: 37.6% vs 34.1%; SAEs: 2.2% vs 2.3%, respectively).

Conclusion In patients with moderate-to-severe COPD, compared with indacaterol monotherapy, once-daily co-administration of glycopyrronium and indacaterol delivered via Breezhaler[®] device provided superior improvements lung function and early post-dose bronchodilation (from Day1), dyspnoea, symptoms and activities, without adversely affecting safety and tolerability.

P233 EFFICACY AND SAFETY OF ONCE-DAILY GLYCOPYRRONIUM COMPARED WITH BLINDED TIOTROPIMUM IN PATIENTS WITH COPD: THE GLOW5 STUDY

¹KR Chapman, ²K Beeh, ³ED Bateman, ²J Beier, ⁴AD D'Urzo, ⁵R Nutbrown, ⁶H Chen, ⁶M Henley, ⁵T Overend, ⁶P D'Andrea; ¹Toronto Western Hospital, Toronto, Canada; ²Respiratory Research Institute, Wiesbaden, Germany; ³University of Cape Town, Cape Town, South Africa; ⁴University of Toronto, Ontario, Canada; ⁵Novartis Horsham Research Centre, Horsham, UK; ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

10.1136/thoraxjnl-2013-204457.385

Background Glycopyrronium, a once-daily long-acting muscarinic antagonist (LAMA), has demonstrated a similar efficacy and safety profile to open-label tiotropium in patients with

moderate-to-severe chronic obstructive pulmonary disease (COPD).¹ The GLOW5 study compared the efficacy and safety of glycopyrronium with blinded tiotropium.

Methods In this multicentre, 12-week, blinded study, patients ≥ 40 years with moderate-to-severe COPD (post-bronchodilator FEV₁ $\geq 30\%$ and $< 80\%$ of the predicted normal, post-bronchodilator FEV₁/FVC < 0.70) and a smoking history of ≥ 10 pack-years were randomised to glycopyrronium 50 μ g (via Breezhaler[®] device) or tiotropium 18 μ g (via HandiHaler[®] device). The primary objective was to demonstrate non-inferiority of glycopyrronium versus tiotropium for trough FEV₁ at Week 12 (non-inferiority margin: -50 mL). Other endpoints included FEV₁ area under the curve from 0 to 4 hours (AUC_{0-4hr}) on Day 1, Transition Dyspnoea Index (TDI), St George's Respiratory Questionnaire (SGRQ), rescue medication use, exacerbation rate, safety and tolerability.

Results Of the 657 patients randomised, (glycopyrronium [n = 327]; tiotropium [n = 330]; mean age: 63.5 years, mean post-bronchodilator FEV₁: 53.5% predicted), 95.9% completed the study. Glycopyrronium demonstrated non-inferiority to tiotropium for trough FEV₁ at Week 12 (Least Squares Mean [LSM] = 1.41L for both the groups; 95% confidence interval [CI]: -0.032, 0.031L). Glycopyrronium had a rapid onset of bronchodilation in the morning as demonstrated by a higher FEV₁ AUC_{0-4hr} on Day 1 compared to tiotropium (LSM treatment difference [Td] = 58mL; p < 0.001). At Week 12, TDI total score (Td = -0.188; p = 0.385), SGRQ total score (Td = 0.65; p = 0.488) and percentage of days with no rescue medication use (Td = -1.5; p = 0.528) were comparable between the groups. No significant treatment difference was observed with respect to rate of moderate/severe COPD exacerbations per year (glycopyrronium 0.38 versus tiotropium 0.35 [rate ratio = 1.10, 95% CI: 0.62, 1.93]; p = 0.754). Overall, the incidence of adverse events was similar in the glycopyrronium (40.4%) and tiotropium (40.6%) groups.

Conclusion Glycopyrronium and blinded tiotropium showed similar improvements in lung function, dyspnoea, health status, exacerbation rate and rescue medication use, with a similar safety and tolerability profile. Onset of bronchodilation with glycopyrronium was significantly more rapid following the first dose.

REFERENCE

1. Kerwin, E. *et al.* Eur Resp J 2012;40:1106-1114.

P234 QVA149 ONCE DAILY IMPROVES LUNG FUNCTION, DYSPNOEA AND HEALTH STATUS INDEPENDENT OF PRIOR MEDICATIONS AND DISEASE SEVERITY: THE SHINE STUDY

¹KR Chapman, ²ED Bateman, ³N Gallagher, ⁴H Hu, ⁴D Banerji; ¹Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Canada; ²Department of Medicine, University of Cape Town, Cape Town, SA; ³Novartis Horsham Research Centre, West Sussex, UK; ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

10.1136/thoraxjnl-2013-204457.386

Introduction QVA149 is a novel, inhaled, once-daily, fixed-dose combination of the long-acting β_2 -agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) in development for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The SHINE study compared the effects of QVA149 110/50 g, indacaterol 150 g, glycopyrronium 50 g, tiotropium 18 g and placebo in

Abstract P234 Table 1. Lung function, dyspnoea and health status improvements in QVA149 vs placebo subgroup analyses based on prior medication use and disease severity.

LSM (SE) treatment difference of QVA149 vs placebo				
1	FEV ₁ AUC _{5min-4h} (L)	Trough FEV ₁ (L)	TDI total score	SGRQ total score
Prior medication use				
-agonist plus steroid	0.34 (0.030)***	0.19 (0.030)***	1.21 (0.406)**	-4.09 (1.705)*
LABA	0.36 (0.059)***	0.25 (0.058)***	0.71 (0.798) ^{ns}	-0.34 (3.103) ^{ns}
LAMA	0.33 (0.028)***	0.22 (0.029)***	1.48 (0.443)***	-5.94 (1.770)***
SABA	0.37 (0.032)***	0.22 (0.031)***	1.29 (0.430)**	-3.10 (1.780) ^{ns}
SAMA	0.30 (0.074)***	0.18 (0.073)*	2.27 (1.135)*	-3.24 (4.495) ^{ns}
-agonist plus anticholinergic	0.31 (0.075)***	0.08 (0.079) ^{ns}	1.13 (1.222) ^{ns}	-4.66 (4.935) ^{ns}
None	0.30 (0.033)***	0.17 (0.034)***	0.97 (0.500) ^{ns}	-2.30 (2.198) ^{ns}
COPD severity				
Moderate	0.37 (0.021)***	0.24 (0.021)***	1.17 (0.294)***	-2.74 (1.257)*
Severe	0.26 (0.031)***	0.12 (0.031)***	1.00 (0.433)*	-3.77 (1.840)*

****P*<0.001; ***P*<0.01; **P*<0.05; ns, non-significant
LSM, least squares mean; SABA, short-acting β_2 -agonist; SAMA, short-acting muscarinic antagonist; SE, standard error

patients with COPD.¹ Here, we present the data on improvements in lung function (forced expiratory volume in 1 second area under the curve [FEV₁ AUC_{5 min-4 h}] and trough FEV₁), transition dyspnoea index (TDI) and St George's Respiratory Questionnaire (SGRQ - total score) by prior medication use and COPD disease severity subgroups.

Methods In this 26-week, multicentre, double-blind, parallel-group, placebo- and active-controlled (open-label tiotropium) study, patients aged ≥ 40 years with moderate-to-severe COPD (post-bronchodilator FEV₁/forced vital capacity (FVC) <0.7 and FEV₁ $\geq 30\%$ to <80% predicted) and a smoking history of ≥ 10 pack-years were randomised to receive once-daily QVA149, indacaterol, glycopyrronium, tiotropium or placebo (2:2:2:2:1).

Results Of the 2144 patients (mean age 63.9 years; mean FEV₁ post-bronchodilator 55.2% predicted) who were randomised (QVA149 [*n* = 475], indacaterol [*n* = 477], glycopyrronium [*n* = 475], tiotropium [*n* = 483] and placebo [*n* = 234]), 89.1% completed the study. QVA149 showed significant improvements in lung function, dyspnoea and health status compared with placebo in patient subgroups based on prior medication use and COPD disease severity (Table 1). Additionally, FEV₁ AUC_{5 min-4 h} was significantly improved for QVA149 versus placebo (*p* < 0.001) regardless of the prior medication use and disease severity.

Conclusion With once-daily QVA149, significant improvements were seen in both moderate and severe COPD patients and independent of medications used before recruitment and randomisation into the SHINE study.

REFERENCE

1. Bateman *et al.* Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. *Eur Respir J.* 2013 May 30. [Epub ahead of print].

P235 DUAL-BRONCHODILATION WITH ONCE-DAILY QVA149 IN PATIENTS WITH MODERATE-TO-SEVERE COPD: OVERVIEW OF THE IGNITE PROGRAM

¹D Price, ²K Mezzi, ³MJ Fedele, ³H Chen, ³D Banerji; ¹Centre of Academic Primary Care, University of Aberdeen, Scotland, UK; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

10.1136/thoraxjnl-2013-204457.387

Introduction In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by monotherapy, current treatment strategies recommend the addition of a second bronchodilator with a different mechanism of action. Once-daily QVA149 is a dual bronchodilator combining the long-acting β_2 -agonist indacaterol (IND) and long-acting muscarinic antagonist glycopyrronium (GLY). The IGNITE program comprises a series of randomised

Abstract P235 Table 1. IGNITE data overview

Parameters		Study (N)	Treatment differences (QVA149 vs comparator)				
			PBO	IND	GLY	TIO	SFC
Lung function	SPARK (2224)	Trough FEV ₁ , mL	-	-	70***	60***	-
		FEV ₁ AUC _{0-12h} , mL	200***	70***	90***	80***	-
	SHINE (2144)	FEV ₁ AUC _{0-12h} , mL	330***	130***	130***	120***	-
		ILLUMINATE (523)	-	-	-	-	140***
	BLAZE (247)	FEV ₁ AUC _{0-4h} , mL	250***	-	-	90***	-
Dyspnoea	ILLUMINATE	TDI score	1.37***	-	-	0.49*	-
			-	-	-	-	0.76**
Health status	SPARK	SGRQ score	-	-	-2.07***	-2.69***	-
Rate reduction of exacerbations, %	All	Moderate-to-severe	-	-	12	10	-
			-	-	RR 0.88*	RR 0.90	-
			-	-	RR 0.85***	RR 0.86**	-
	ILLUMINATE	Moderate-to-severe	-	-	-	-	20
		All	-	-	-	-	RR 0.80

p*<0.05; *p*<0.01; ****p*≤0.001; †free combination; GLY=glycopyrronium; IND=indacaterol; PBO=placebo; SFC=salmeterol/fluticasone; RR=rate ratio; TIO=tiotropium